BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

If adopted, the rule would eliminate all cost to Medicare patients for a follow-up colonoscopy after a positive at-home colorectal cancer screening test. A...

November 02, 2022 | News

Irish oncology care platform announces collaboration with NCCN

The Irish-founded oncology software company, ONCOassist, today announces a new agreement with The National Comprehensive Cancer Network® (NCCN®). T...

October 18, 2022 | News

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China reg...

October 17, 2022 | News

Health Canada Approves Illuccix® for Prostate Cancer Imaging

Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the po...

October 14, 2022 | News

First patient treated in Clarity's therapeutic prostate cancer trial

Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...

October 10, 2022 | News

China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

October 10, 2022 | News

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

As Illuccix rolls out to positron emission tomography (PET) sites across the country, Mercy Radiology in Auckland became the first to administer ...

September 30, 2022 | News

Australia approved New treatment for rare cancer cholangiocarcinoma

A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. PEMAZYRE® (pemigat...

September 16, 2022 | News

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

September 14, 2022 | News

Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA)

lacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line...

August 21, 2022 | News

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

Irish oncology care platform announces collaboration with NCCN

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

Health Canada Approves Illuccix® for Prostate Cancer Imaging

First patient treated in Clarity's therapeutic prostate cancer trial

China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

Australia approved New treatment for rare cancer cholangiocarcinoma

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test

Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors

Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management

Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA)

Stay Connected